Immatics N.V.

IMTXNASDAQ🇺🇸

Healthcare · Biotechnology

$9.68▼ 1.53%

Last updated: 20h ago

52-Week Range

$3.30

$12.41

Company Overview

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two di

Valuation

PER (TTM)—

Forward PER-5.32

PBR2.23

PSR25.67

EV/EBITDA-4.54

Market Cap$1.30B

Profitability

ROE-37.10%

ROA-18.08%

Net Margin0.00%

Operating Margin-196.76%

Growth & Stability

Revenue Growth-64.90%

Earnings Growth—

Debt-to-Equity3.2

Current Ratio11.72

Beta1.35

Dividends

Dividend Yield—

Payout Ratio0.0%

Trading Info

Prev Close$9.83

Volume227K

Avg Volume466K

Employees589

Related News

[StockHub Alert] Sharp Rise 5, Sharp Drop 1, Volume Surge 1

🚀 Sharp Rise • BioCryst Pharmaceuticals, Inc. ($BCRX) $9.06 +10.3% • BellRing Brands, Inc. ($BRBR) $18.41 +9.4% • Ziff Davis, Inc. ($ZD) $42.46 +7.6% • Immatics N.V. ($IMTX) $9.89 +7.0% • Cohu, Inc. ($COHU) $28.97 +6.3% 💥 Sharp Drop • Petco Health and Wellness Compa ($WOOF) $3.41 -5.8% 📊 Volume Surge • BioCryst Pharmaceuticals, Inc. ($BCRX) $9.06 +10.3% (거래량 3.2배)

StockHub

🧮 Investment Calculators

Compound Interest · Dividend Tax · DCA · Capital Gains Tax · Loan & more

→